Plain-English translation of NCT06231381 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help treat people having a severe flare of generalized pustular psoriasis (GPP), a rare condition where the skin develops widespread pustules. You would receive either the medication or a placebo (a non-active treatment) as a single intravenous infusion, and researchers would monitor how well it works and whether it is safe.
Generalized pustular psoriasis is a serious condition that can suddenly worsen dramatically, and people experiencing these severe flares need better treatment options. This trial is testing whether this medication might help control these dangerous flares more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would be admitted to a hospital where you would receive a single intravenous infusion of either the medication or placebo on day one. You would stay hospitalized for at least 8 days so doctors can closely monitor your response and watch for any side effects. After that, your doctor would decide when you could go home based on how your skin is improving. You would then have follow-up visits and check-ins for up to 20 weeks to see how well the treatment worked and ensure you remain healthy.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China